Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Introduction

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder that causes progressive weakness and sensory loss in the arms and legs. It is the chronic counterpart of Guillain-Barré syndrome and is characterized by demyelination of peripheral nerves. ^{1"Chronic inflammatory demyelinating polyradiculoneuropathy" (2017)2017 · PMID 28446769Open reference} CIDP represents the most common chronic autoimmune neuropathy, with an estimated prevalence of 1-9 per 100,000 individuals worldwide. The disease typically presents in adults between the ages of 40-60, though it can occur at any age, including in children and the elderly.

The pathophysiology of CIDP involves a dysregulated immune response targeting peripheral nerve myelin. Both cellular and humoral immune mechanisms contribute to disease pathogenesis, with T-cell activation, macrophage-mediated demyelination, and antibody-mediated complement activation all playing roles. ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference} This immune attack results in segmental demyelination, onion bulb formation (characteristic concentric layers of Schwann cell processes), and varying degrees of axonal loss, which together produce the clinical manifestations of progressive motor and sensory deficits.

Epidemiology and Risk Factors

CIDP has an estimated annual incidence of 1-2 per 100,000 population, with a prevalence ranging from 1.6 to 10.3 per 100,000 depending on geographic region and diagnostic criteria used. ^{1"Chronic inflammatory demyelinating polyradiculoneuropathy" (2017)2017 · PMID 28446769Open reference} The disease affects both genders, with a slight male predominance (approximately 1.3:1 male-to-female ratio). Peak incidence occurs in the fifth and sixth decades of life, though childhood onset accounts for approximately 10-15% of cases.

Several risk factors have been implicated in CIDP susceptibility, including:

• Genetic predisposition: Certain HLA alleles (particularly HLA-DRB1) have been associated with increased CIDP risk. ^{3"Genetics of CIDP susceptibility" (2023)2023 · PMID 36758371Open reference}

• Preceding infections: Molecular mimicry following infections (particularly with Campylobacter jejuni, cytomegalovirus, and hepatitis viruses) may trigger autoimmune responses

• Autoimmune comorbidities: CIDP frequently co-occurs with other autoimmune conditions including diabetes mellitus, systemic lupus erythematosus, and Sjögren’s syndrome

Clinical Presentation

Typical Presentation

CIDP typically presents with a subacute onset over weeks to months of progressive symmetric motor and sensory symptoms. The clinical phenotype can vary significantly between patients, leading to recognition of distinct clinical variants. ^{4"CIDP subtypes and classification" (2018)2018 · PMID 29938526Open reference}

Motor symptoms include:

• Progressive limb weakness, typically beginning in the distal muscles and progressing proximally

• Difficulty with fine motor tasks (buttoning, writing, manipulating small objects)

• Gait instability, particularly on uneven surfaces or when climbing stairs

• Foot drop leading to steppage gait

• Facial weakness (in severe cases)

• Respiratory muscle involvement (in advanced disease)

Sensory symptoms include:

• Numbness or reduced sensation, often in a stocking-glove distribution

• Tingling or paresthesias

• Sensory ataxia leading to poor balance

• Pain (present in approximately 20-30% of patients), often described as burning or deep aching

Clinical Variants

Several distinct clinical variants of CIDP have been recognized: ^{4"CIDP subtypes and classification" (2018)2018 · PMID 29938526Open reference}

Variant	Characteristics
Typical CIDP	Classic presentation with progressive, symmetric, proximal and distal weakness with sensory involvement
Pure sensory CIDP	Predominantly sensory symptoms with minimal or no motor involvement
Pure motor CIDP	Prominent motor weakness without significant sensory deficits
Focal/Multifocal (MADSAM)	Asymmetric or multifocal presentation, also known as Lewis-Sumner syndrome
Distal acquired demyelinating symmetric (DADS)	Predominantly distal weakness and sensory loss
Pediatric CIDP	Presents in children with often more prominent sensory features

Examination Findings

Physical examination typically reveals:

• Motor: Symmetric proximal and distal weakness, more pronounced in lower extremities

• Sensory: Reduced vibration sense and proprioception, often in a stocking distribution

• Reflexes: Diminished or absent deep tendon reflexes, a hallmark finding

• Ataxia: Sensory ataxia secondary to proprioceptive loss

• Cranial nerves: May be involved in up to 15% of cases, with facial weakness most common

• Autonomic: Orthostatic hypotension, bladder dysfunction in severe cases

Pathophysiology

CIDP is characterized by immune-mediated damage to the myelin sheath of peripheral nerves. The exact trigger is unknown, but it is thought to involve both cellular and humoral immune responses. T-cells, macrophages, and antibodies target myelin proteins and lipids, leading to demyelination and subsequent nerve conduction deficits. In some cases, CIDP may be associated with other conditions such as diabetes, HIV, or monoclonal gammopathy. ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}

Cellular Immune Mechanisms

The cellular immune response in CIDP involves both CD4+ and CD8+ T-cells:

• CD4+ T-helper cells become activated against myelin antigens and release pro-inflammatory cytokines (IFN-γ, IL-17, TNF-α)

• CD8+ cytotoxic T-cells directly attack myelin-producing Schwann cells

• Macrophages are recruited to peripheral nerves and mediate demyelination through phagocytosis and release of toxic molecules

• Th17 cells and the IL-23/IL-17 axis contribute to chronic inflammation

Humoral Immune Mechanisms

Antibody-mediated mechanisms play a significant role in CIDP pathogenesis:

• Anti-MAG antibodies are present in approximately 10% of CIDP patients, associated with predominantly distal neuropathy

• Antibodies against peripheral myelin proteins (P0, PMP22, P2) have been identified in subsets of patients

• Autoantibodies against neurofascin-155 have been associated with treatment-resistant CIDP

• Complement activation following antibody binding leads to formation of the membrane attack complex and myelin destruction

Pathological Features

Nerve biopsy findings in CIDP include:

• Segmental demyelination with preservation of axonal integrity in early stages

• Onion bulb formation - concentric layers of Schwann cell processes surrounding axons

• Inflammatory infiltrates containing T-cells and macrophages

• Endoneurial edema

• In later stages: axonal degeneration secondary to chronic demyelination

Diagnosis

Diagnosis is based on clinical presentation, nerve conduction studies showing demyelination, and cerebrospinal fluid analysis (elevated protein with normal cell count). Nerve biopsy may be performed in atypical cases.

Diagnostic Criteria

The EFNS/PNS guidelines establish diagnostic criteria requiring:

1. Clinical criteria: Progressive motor and sensory dysfunction in more than one limb, developing over ≥8 weeks

2. Electrodiagnostic criteria: Evidence of demyelination in ≥2 nerves:

   • Conduction velocity <70% of lower limit in at least one nerve

   • Distal latency >150% of upper limit

   • F-wave latency >150% of upper limit

   • Temporal dispersion or conduction block

3. CSF criteria: Elevated protein (>0.45 g/L) with normal cell count (<10 cells/μL)

4. Exclusion criteria: Other causes of neuropathy, including metabolic, toxic, hereditary

Nerve Conduction Studies

Nerve conduction studies (NCS) and electromyography (EMG) are essential for diagnosis:

• Demyelinating features: Reduced conduction velocities, prolonged distal latencies, prolonged F-wave latencies, temporal dispersion

• Conduction block: Significant reduction in compound muscle action potential amplitude proximally versus distally

• Abnormalities: Typically most pronounced in motor nerves, with sensory involvement evident in most patients

• Axonal loss: May be present in chronic or treatment-non-responsive cases

Cerebrospinal Fluid Analysis

Cerebrospinal fluid (CSF) analysis typically shows:

• Elevated protein: 0.5-3.0 g/L in approximately 80% of patients

• Normal cell count: <10 mononuclear cells/μL (pleocytosis suggests alternative diagnosis)

• Albuminocytologic dissociation: Elevated protein with normal cell count

Imaging

Nerve ultrasound and MRI can provide supportive evidence:

• MRI: Enhancement of nerve roots, nerve hypertrophy, T2 hyperintensity

• Ultrasound: Enlarged cross-sectional area of peripheral nerves, particularly at entrapment sites and nerve roots

Biomarkers

Recent research has identified potential biomarkers: ^{5"Neurofilament light chain as CIDP biomarker" (2019)2019 · PMID 31219257Open reference 6"NF-L in CIDP disease activity" (2023)2023 · PMID 37489542Open reference}

• Neurofilament light chain (NfL): Elevated in serum and CSF; correlates with disease activity and treatment response

• Neurofilament heavy chain (NfH): Similar predictive value

• Cytokine profiles: Elevated IL-17, IFN-γ in active disease

Differential Diagnosis

CIDP must be distinguished from other demyelinating neuropathies including:

• Guillain-Barré syndrome (acute inflammatory demyelinating polyradiculoneuropathy)

• Multifocal motor neuropathy (MMN) - typically without sensory involvement

• Charcot-Marie-Tooth Disease (hereditary) - usually more gradual onset, family history

• Diabetic neuropathy - metabolic etiology, typically axonal

• Vasculitic neuropathy - systemic features, mononeuritis multiplex pattern

Treatment

First-line treatments for CIDP include corticosteroids (such as prednisone), intravenous immunoglobulin (IVIG), and plasma exchange (plasmapheresis). These treatments aim to suppress the immune system’s attack on the myelin sheath. IVIG is often preferred due to its rapid onset of action and favorable side effect profile. Immunosuppressive agents may be considered for patients who do not respond to first-line therapies. ^{7"Guidelines on management of CIDP" (2021)2021 · PMID 33448163Open reference}

First-Line Therapies

Treatment	Mechanism	Administration	Efficacy
IVIG	Immunomodulation via Fc receptor blockade, complement inhibition	2 g/kg over 2-5 days, repeat as needed	60-80% response rate
Plasma exchange	Removal of pathogenic antibodies	4-6 exchanges over 2-3 weeks	70-80% response rate
Corticosteroids	Broad immunosuppression	Prednisone 1 mg/kg/day, taper over months	60-70% response rate

Corticosteroids

Oral corticosteroids (prednisone, prednisolone) or intravenous methylprednisolone are commonly used: ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}0

• Dosing: 1 mg/kg/day orally or 1 g IV daily for 3-5 days

• Duration: Gradual taper over 6-12 months based on response

• Side effects: Weight gain, diabetes, osteoporosis, mood changes, infections

• Relapse rate: Up to 40% during or after taper

Intravenous Immunoglobulin

IVIG is often preferred due to its rapid onset of action and favorable side effect profile: ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}1

• Mechanism: Multiple immunomodulatory effects including Fc receptor blockade, cytokine modulation, neutralization of pathogenic antibodies

• Dosing: 2 g/kg total dose (typically 0.4 g/kg/day for 5 days)

• Maintenance: May be given as repeat pulses or ongoing infusions (1 g/kg every 2-4 weeks)

• Side effects: Headache, aseptic meningitis, anaphylaxis (rare), thromboembolic events, hemolysis

• Response: 60-80% of patients respond, often within days to weeks

Plasma Exchange

Plasma exchange (PLEX) is particularly useful for severe or rapidly progressive disease: ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}2

• Mechanism: Removal of circulating autoantibodies and immune complexes

• Protocol: 4-6 exchanges over 2-3 weeks, each 1-1.5 plasma volumes

• Efficacy: Comparable to IVIG, with response within days to weeks

• Access: Requires central venous access (femoral or subclavian)

• Complications: Infection, bleeding, electrolyte disturbances, hemodynamic instability

Second-Line and Third-Line Therapies

For patients refractory to first-line treatments: ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}3

Agent	Mechanism	Typical Response
Azathioprine	Purine analog, T-cell suppression	30-40% after 3-6 months
Methotrexate	Folate antagonist, lymphocyte inhibition	30-40% after 3-6 months
Cyclosporine	Calcineurin inhibitor	40-50% response
Mycophenolate mofetil	IMP dehydrogenase inhibitor	40-50% response
Cyclophosphamide	Alkylating agent	50-60% response
Rituximab	Anti-CD20, B-cell depletion	Variable, particularly in autoantibody-positive

Novel and Emerging Therapies

Recent therapeutic developments include: ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}4 ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}5

• Efgartigimod: FcRn antagonist promoting IgG degradation; positive Phase 2 results in CIDP

• Ravulizumab: Long-acting complement C5 inhibitor; Phase 3 trial ongoing

• Alemtuzumab: Anti-CD52; reserved for severe refractory cases

Prognosis

The prognosis for CIDP varies significantly among patients. Some individuals experience a monophasic course with complete recovery, while others have a relapsing-remitting or progressive pattern. Early diagnosis and treatment are associated with better outcomes. Long-term follow-up is essential to monitor for treatment response and adjust therapy as needed. ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}6

Outcome Patterns

Approximately one-third of CIDP patients follow each of these patterns: ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}7

1. Monophasic: Single episode with complete or near-complete recovery

2. Relapsing-remitting: Episodes of relapse with partial or complete recovery between episodes

3. Progressive: Gradual deterioration over time despite treatment

Prognostic Factors

Favorable prognosis:

• Early treatment initiation

• Pure motor phenotype

• Typical CIDP (vs. variants)

• Good initial treatment response

Poor prognosis:

• Late treatment initiation

• Axonal loss on electrodiagnostics

• Older age at onset

• Demyelinating variants with axonal loss

• Associated comorbidities (diabetes, autoimmune disease)

Long-Term Outcomes

Long-term studies show:

• Functional outcomes: Approximately 60-70% achieve independent mobility with treatment

• Treatment dependence: Most patients require ongoing immunotherapy

• Quality of life: Improved with effective treatment but often remains below population norms

• Mortality: Slightly increased compared to age-matched population, primarily due to complications

Research Directions

Current research focuses on identifying biomarkers for treatment response, understanding the underlying autoimmune mechanisms, and developing more targeted therapies. Clinical trials are investigating novel immunosuppressive agents, stem cell therapy, and gene therapy approaches for CIDP. ^{2"CIDP pathophysiology and biomarkers" (2016)2016 · PMID 27324842Open reference}8

Active Research Areas

1. Biomarker development: Neurofilament light chain as disease activity marker

2. Novel biologics: FcRn antagonists, complement inhibitors, B-cell targeted therapies

3. Treatment optimization: Predictors of treatment response, personalized medicine approaches

4. Pathophysiology: Identification of specific antigenic targets, genetic susceptibility factors

5. Pediatric CIDP: Distinct features and optimal treatment approaches

Clinical Trials

Multiple Phase 2 and Phase 3 trials are ongoing, investigating:

• Efgartigimod (argenx) - FcRn antagonist

• Ravulizumab (Alexion) - Complement inhibition

• Rozanolixizumab (UCB) - FcRn antagonist

• Various biosimilars and generic IVIG formulations

Neurodegeneration Connections

While CIDP is primarily an autoimmune neuropathy, it intersects with neurodegenerative disease research in several important ways:

Shared Mechanisms with Neurodegenerative Diseases

• Neuroinflammation: Chronic inflammatory processes in CIDP mirror neuroinflammatory mechanisms in AD, PD, and ALS

• Myelin dysfunction: Similar pathways involved in demyelination and myelin repair

• Axonal degeneration: Common final pathway with shared molecular mechanisms

Research Methodologies

Techniques developed for CIDP research have applications in neurodegeneration:

• Nerve conduction studies adapted for CNS demyelination research

• Biomarker development for NfL applicable across neurodegenerative diseases

• Immunomodulatory therapies with potential broader applications

See Also

• Guillain-Barré Syndrome

• Multiple Sclerosis

• Peripheral Neuropathy

• Multifocal Motor Neuropathy

External Links

• NINDS CIDP Information

• Mayo Clinic - CIDP

• Foundation for Peripheral Neuropathy

• GBS/CIDP Foundation International

Recent Research (2024-2026)

• Nerve Ultrasound in Pediatric Polyneuropathies: A Systematic Review. (2026 Apr) - Neuropediatrics

• POEMS syndrome: a neuromuscular perspective. (2026 Mar 13) - Journal of neurology, neurosurgery, and psychiatry

• Correspondence: “Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Comparative Study of Magnetic Resonance Neurography and High-Resolution Nerve Ultrasound in the Assessment of Brachial Plexus”. (2026 Mar 12) - Annals of Indian Academy of Neurology

• Biallelic Variants in RNU6ATAC Result in a Minor Spliceopathy Characterized by Transcriptome-Wide Minor Intron Retention Events and Short Stature with Variable Multisystem Manifestations. (2026 Mar 9) - HGG advances

• Residual immune activation in cidp remission: the contribution of macrophage-derived cytokines and chemokines. (2026 Mar 7) - Acta neurologica Belgica